3
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Bystander effect of antitumour therapy

Pages 987-988 | Published online: 03 Mar 2008
 

Abstract

This application comes from one of the leading groups developing clinical applications for gene therapy at the US National Institutes of Health. The invention involves the use of genetically modified mouse fibroblast cells to deliver a defective retrovirus at high titre to cells within a tumour or body cavity. This retrovirus carries a non-mammalian gene encoding a prodrugactivating enzyme so that transduced target cells are made sensitive to the cytotoxic effects of an otherwise harmless prodrug (gancyclovir for the herpes simplex thymidine kinase gene, for instance). Since the retrovirus-producing cells carry the same prodrug activating (suicide) gene they can be destroyed after the therapeutic gene transfer has been achieved. The application demonstrates that gene transfer into all target cells is not required in order to produce complete tumour regression on exposure to the cytotoxic prodrug due to bystander effects on untransduced cells.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.